跳至主要内容
临床试验/NCT02203383
NCT02203383
暂停
不适用

Sleep Disordered Breathing in Patients With Implanted Cardiac Devices: Assessment of the Change in Sensitivity to Carbon Dioxide With Cardiac Resynchronization Therapy.

Royal Brompton & Harefield NHS Foundation Trust1 个研究点 分布在 1 个国家目标入组 40 人2014年6月

概览

阶段
不适用
干预措施
未指定
疾病 / 适应症
Sleep Disordered Breathing
发起方
Royal Brompton & Harefield NHS Foundation Trust
入组人数
40
试验地点
1
主要终点
The change in gradient of minute ventilation vs end tidal CO2 before and after CRT (the hypercapnic ventilatory response).
状态
暂停
最后更新
9年前

概览

简要总结

Central Sleep Apnoea (CSA) affects up to half of patients with severe heart failure and is associated with a poor prognosis. CSA is manifest as episodes of deep breathing interspersed with very shallow or absent breathing and is largely due to an exaggerated response to rising carbon dioxide in the blood, which normally drives how hard we breathe. Cardiac Resynchronization therapy (CRT), in which a pacemaker is implanted to improve co-ordinated contraction of the heart, has been shown to reduce the severity of CSA in some patient groups. We aim to determine whether this improvement is due to normalization of the body's response to carbon dioxide in the blood. Our hypothesis is that CRT improves CSA by normalizing the brain's response to carbon dioxide.

详细描述

Sleep disordered Breathing is common in heart failure, affecting around half of patients. This may be Obstructive Sleep Apnoea due to loss of pharyngeal muscle tone (OSA, associated with obesity and snoring and predisposing to hypertension, heart attack and stroke) or Central Sleep Apnoea (CSA). CSA is particularly prevalent in severe heart failure and associated with an adverse prognosis. The mechanism involves reflex hyperventilation due to pulmonary oedema, exaggerated chemosensor response to hypercapnoea associated with increased sympathetic nervous system activation and a prolonged circulation time. It is known that CRT improved CSA in 'responders' but the mechanism is unknown. We hypothesis that CRT normalizes the respiratory response to carbon dioxide (the hypercapnic ventilatory response - HCVR). We will screen patients undergoing CRT with an Embletta sleep study to identify a group with moderate to severe CSA and a group with no sleep apnoea (controls). Patients will undergo assessment of the hypercapnic ventilatory response with a Read Re-Breathe test prior to device implantation and 6 weeks and 6 months afterwards. The gradient of minute ventilation vs PaCO2 will be compared.

注册库
clinicaltrials.gov
开始日期
2014年6月
结束日期
2017年10月
最后更新
9年前
研究类型
Observational
性别
All

研究者

入排标准

入选标准

  • Heart failure with reduced ejection fraction (\<40%)
  • Either no significant sleep disordered breathing or moderate to severe CSA
  • Able to consent to the study
  • Ambulatory
  • Aged 18-100 years

排除标准

  • Patients on Non-Invasive Ventilation
  • Predominant OSA
  • Unable to consent or attend for the study

结局指标

主要结局

The change in gradient of minute ventilation vs end tidal CO2 before and after CRT (the hypercapnic ventilatory response).

时间窗: 6 weeks and 6 months

次要结局

  • Change in left ventricular ejection fraction(6 weeks and 6 months)
  • Change in resting PaCO2(6 weeks and 6 months)
  • 6 minute walk distance(6 weeks and 6 months)
  • Change in plasma B-Type Natriuretic Peptide level(6 weeks and 6 months)

研究点 (1)

Loading locations...

相似试验